New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
08:04 EDTLGNDLigand earns milestone from SAGE Therapeutics for SAGE-547
Ligand Pharmaceuticals announced that it has earned a $150,000 milestone payment from SAGE Therapeutics relating to the earlier commencement by SAGE of a Phase 1/2 clinical trial of SAGE-547 for the treatment of super-refractory status epilepticus, a life-threatening seizure condition in which the brain is in a state of persistent seizure. SAGE-547 is an intravenous agent in Phase 1/2 clinical development as an adjunctive therapy, a therapy combined with current therapeutic approaches, for the treatment of SRSE. SAGE utilizes Ligandís Captisol technology to develop SAGE-547 for status epilepticus and traumatic brain injury. In 2013, Ligand entered into a platform license agreement with SAGE for the development and commercialization of Captisol-enabled therapeutics for a broad range of debilitating central nervous system conditions. Elements of that agreement were also recently expanded to cover additional therapy areas for certain compounds.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
13:17 EDTLGNDLigand reports partner SAGE receives fast track designation for SAGE-547
Subscribe for More Information
July 17, 2014
08:02 EDTLGNDLigand sees Q2 revenue $10.6M, above previous guidance of $9M-$9.5M
Subscribe for More Information
08:01 EDTLGNDLigand board authorizes $10M repurchase program
Subscribe for More Information
July 16, 2014
09:41 EDTLGNDLigand management to meet with Roth Capital
Subscribe for More Information
July 14, 2014
07:20 EDTLGNDControlled Released Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use